Trials / Terminated
TerminatedNCT00941486
FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis
A Randomized, Masked, Vehicle-controlled Clinical Trial to Assess the Safety and Efficacy of PVP-I (0.4%)/Dexamethasone (0.1%) Ophthalmic Suspension (Foresight Biotherapeutics, Inc) in the Treatment of Acute Adenoviral Conjunctivitis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- 3 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy of FST-100 (PVP-I 0.4% and dexamethasone 0.1%) Ophthalmic Suspension in the treatment of suspected acute adenoviral conjunctivitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FST-100 Ophthalmic Suspension | FST-100 (PVP-I 0.4% and dexamethasone 0.1%). A regimen of 2 drops 4 times a day while awake for 5 days. |
| DRUG | Placebo | A regimen of 2 drops 4 times a day while awake for 5 days. |
Timeline
- Start date
- 2009-06-30
- Primary completion
- 2010-06-30
- Completion
- 2010-06-30
- First posted
- 2009-07-17
- Last updated
- 2021-08-24
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00941486. Inclusion in this directory is not an endorsement.